title: [Management of cancer-related fatigue].
abstract: BACKGROUND
  Cancer-related fatigue is very common but its management remains frustrating. We thus sought to review current knowledge in this field: epidemiologic data, pathophysiological mechanisms, assessment, and treatment.
  
  
  METHODS
  We queried the Medline database for all articles on this topic published between 1997 and 2007 and analyzed the articles published in English and French, as well as some of the essential earlier work.
  
  
  RESULTS
  Approximately 60 to 96% of patients treated for cancer report fatigue. The prevalence of fatigue that persists after the disease is considered to be in remission is substantial. Fatigue is a multidimensional problem with biological, psychological, social, and personal aspects. Physical causes must be systematically considered (comorbidities, anemia, and endocrine disorders), but most cases remain unresolved. Many may be attributed to deconditioning. There is not now any pharmacological therapy that treats this symptom effectively. Some psychostimulants are being tested, but the initial results of the studies are contradictory. Exercise is the intervention for which there is the most evidence of effectiveness.
  
  
  CONCLUSIONS
  Cancer-related fatigue is a very common symptom for which no specific cause can usually be identified. In this situation, rest may be more harmful than exercise.
authors.affiliation: Service de médecine interne - oncologie, Hôpital d'instruction des armées Desgenettes, F-69003 Lyon, France. m.pavic@numericable.com
authors.forename: Michel
authors.initials: M
authors.lastname: Pavic
authors.forename: Pascal
authors.initials: P
authors.lastname: Sève
authors.forename: Hugues
authors.initials: H
authors.lastname: Rousset
authors.forename: Philippe
authors.initials: P
authors.lastname: Debourdeau
mesh_terms: D001247:Asthenia / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D005221:Fatigue / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D009369:Neoplasms / Q000150:complications*